ArticleMolecular neurobiology2025
Phenserine Mitigates Neuroinflammation, Apoptosis, and Behavioural Deficits to Enhance Motor Function and Recovery in a Mouse Model of Spinal Cord Injury.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting glial scar formation for spinal cord injury: mechanisms, strategies, and research progress review.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury is a debilitating medical condition that results in paralysis and loss of sensorimotor function below the level of injury. The pathological cascade following the injury involves inflammation, apoptosis, blood-spinal cord barrier integrity disruption, axonal damage, glial scarring, and demyelination. This study evaluates the therapeutic potential of phenserine, a lipophilic phenyl carbamate derivative with neuroprotective, anti-inflammatory, and anti-apoptotic properties, in a compression-induced spinal cord injury model in C57bl/6 mice. Intraperitoneal administration of phenserine (5 mg/kg, twice daily for 5 days) significantly reduced inflammatory responses and blood-spinal cord barrier permeability at 1 day post-injury. By 7 days, it attenuated apoptotic signalling, and by 28 days, it reduced glial scarring and enhanced markers of axonal integrity and myelination. Neurobehavioral assessments further indicated that phenserine treatment improved motor and functional recovery outcomes. Collectively, our findings highlight phenserine as a promising therapeutic candidate that targets multiple secondary injury mechanisms to promote neuroprotection and functional restoration following spinal cord injury, marking a novel approach in managing traumatic spinal cord injury.
Indexed as
Identifiers
40580267What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.